Phase I Study on VEGF Vaccination in Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2020

Study Completion Date

January 1, 2020

Conditions
Metastatic Cancer
Interventions
BIOLOGICAL

hVEGF26-104/RFASE

Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.

Trial Locations (1)

1081 HV

VU University Medical Center, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Immunovo B.V.

UNKNOWN

lead

Amsterdam UMC, location VUmc

OTHER

NCT02237638 - Phase I Study on VEGF Vaccination in Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter